?-Secretase inhibitors and modulators for Alzheimer's disease

被引:115
|
作者
Wolfe, Michael S. [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
关键词
active site; allosteric sites; amyloid; chemical probes; docking site; protease; AMYLOID PRECURSOR PROTEIN; TRANSGENIC MOUSE MODEL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TARGET GAMMA-SECRETASE; C-TERMINAL FRAGMENT; BETA-PROTEIN; THERAPEUTIC TARGET; ACTIVE-SITE; PRESENILIN; DISCOVERY;
D O I
10.1111/j.1471-4159.2011.07501.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
-Secretase is a membrane embedded aspartyl protease complex with presenilin as the catalytic component. Along with beta-secretase, this enzyme produces the amyloid beta-protein of Alzheimers disease (AD) from the amyloid beta-protein precursor. Because of its key role in the pathogenesis of AD, ?-secretase has been a prime target for drug discovery, and many inhibitors of this protease have been developed. The therapeutic potential of these inhibitors is virtually negated by the fact that beta-secretase is an essential part of the Notch signaling pathway, rendering the compounds unacceptably toxic upon chronic exposure. However, these compounds have served as useful chemical tools for biological investigations. In contrast, beta-secretase modulators continue to be of keen interest as possible AD therapeutics. These modulators either shift amyloid beta-protein production to shorter, less pathogenic peptides or inhibit the proteolysis of amyloid beta-protein precursor selectively compared to that of Notch. The various chemical types of inhibitors and modulators will be discussed, along with their use as probes for basic biology and their potential as AD therapeutics.
引用
收藏
页码:89 / 98
页数:10
相关论文
共 50 条
  • [1] Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease
    Olson, Richard E.
    Marcin, Lawrence R.
    [J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 42, 2007, 42 : 27 - 47
  • [2] Secretase inhibitors and modulators for Alzheimer's disease treatment
    Tomita, Taisuke
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2009, 9 (05) : 661 - 679
  • [3] γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes
    Imbimbo, Bruno P.
    Giardina, Giuseppe A. M.
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (12) : 1555 - 1570
  • [4] Secretase Inhibitors and Modulators as a Disease-Modifying Approach Against Alzheimer's Disease
    Gijsen, Harrie J. M.
    Bischoff, Francois P.
    [J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 47, 2012, 47 : 55 - 69
  • [5] Disease-Modifying Approach to the Treatment of Alzheimer's Disease From α-Secretase Activators to γ-Secretase Inhibitors and Modulators
    Panza, Francesco
    Solfrizzi, Vincenzo
    Frisardi, Vincenza
    Capurso, Cristiano
    D'Introno, Alessia
    Colacicco, Anna M.
    Vendemiale, Gianluigi
    Capurso, Antonio
    Imbimbo, Bruno P.
    [J]. DRUGS & AGING, 2009, 26 (07) : 537 - 555
  • [6] Disease-Modifying Approach to the Treatment of Alzheimer’s DiseaseFrom α-Secretase Activators to γ-Secretase Inhibitors and Modulators
    Francesco Panza
    Vincenzo Solfrizzi
    Vincenza Frisardi
    Cristiano Capurso
    Alessia D’Introno
    Anna M. Colacicco
    Gianluigi Vendemiale
    Antonio Capurso
    Bruno P. Imbimbo
    [J]. Drugs & Aging, 2009, 26 : 537 - 555
  • [7] γ-Secretase inhibitors and Alzheimer's disease
    Roberts, SB
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (12) : 1579 - 1588
  • [8] Secretase inhibitors for Alzheimer's disease
    Kornilova, AY
    Wolfe, MS
    [J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 38, 2003, 38 : 41 - 50
  • [9] Development and Mechanism of γ-Secretase Modulators for Alzheimer's Disease
    Crump, Christina J.
    Johnson, Douglas S.
    Li, Yue-Ming
    [J]. BIOCHEMISTRY, 2013, 52 (19) : 3197 - 3216
  • [10] Untangling Alzheimer's disease with β-secretase inhibitors
    Dorrell, S
    [J]. DRUG DISCOVERY TODAY, 2000, 5 (08) : 316 - 317